IMMUNOLOGICAL ADJUVANT BASED ON NANOPARTICLES FOR VACCINES AGAINST HIGHLY PATHOGENIC INFLUENZA VIRUSES STRAINS Russian patent published in 2014 - IPC C12N15/863 B82B3/00 

FIELD: biotechnology.

SUBSTANCE: immunoadjuvant is claimed representing hydroxyapatite nanoparticles with adsorbed synthetic peptide - CXCR ligand of 1 2 and receptors. The vaccine against influenza is presented, comprising the claimed immunoadjuvant and chimeric protein NS-ESAT. FIELD: On inorganic nanoparticles the adsorbed peptide Pro-Pro-Gly-Pro-His (PPGPH) which represents the ligand of CXCR 1 and 2. The base of solving the problem set was obtaining complexes of hydroxyapatite nanoparticles with the chimeric protein NS-ESAT. The protocols of obtaining these complexes are developed, as well as the effectiveness of their generation was quantitatively studied. As the results of tests of the complexes obtained on laboratory animals the data is obtained giving evidence that these complexes are capable to stimulate a cellular link of immune response more effectively than the commercial adjuvant. On this account the resulting complexes may be considered as a potential vaccine component, particularly anti-influenza, particularly against such highly pathogenic strains of influenza virus as H5N1, H1N1, and others. As a result of the studies carried out the affinity of hydroxyapatite nanoparticles to chimeric protein NS-ESAT-6 is revealed. A fragment of the influenza virus NS1 protein (125 amino acid residues long) having high affinity for phosphate groups, provides an increased affinity of the fusion protein to hydroxyapatite nanoparticles. The immunological adjuvant is proposed to use as nanoparticles of hydroxyapatite, which, according to the results of tests on laboratory animals is able to stimulate more effectively than the commercial adjuvant the cellular link of immune response. In addition, the use of the sorption properties of hydroxyapatite is proposed for creation of nanocompositions comprising individual immunomodulators stimulating the immune response to the target antigens.

EFFECT: increased immunogenicity of vaccines with use of inorganic nanoparticles.

3 cl, 4 dwg